FDA 2002 NME approval times (correction)
Executive Summary
FDA's average approval time for new molecular entities approved in 2002 is 17 months. "The Pink Sheet" (1Jan. 6, p. 10) incorrectly reported that Alliance Pharmaceuticals' Imagent NDA had been resubmitted and therefore miscalculated the approval time average. Imagent (perflexane) was approved in 31.6 months...
You may also be interested in...
FDA Faster Approval Times For 2002 NMEs Aided By Resubmissions
The average total approval time for new molecular entities cleared by FDA in 2002 was 15.2 months, an analysis of new drug approvals shows
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.